

SUPPLEMENTAL MATERIAL

Peppia et al., <http://www.jem.org/cgi/content/full/jem.20121172/DC1>**Table S1.** Characteristics of CHB patients with available paired PBMC and liver biopsy specimens

Patients (n = 21; HLAA2 ⁻)	Age (median, 38; range, 28-54)	Sex (F/M = 4:17)	HBeAg ⁺ 6/21	HBV DNA (IU/ml; median, 7503; range: 36- 5.19 x 10 ⁸)	ALT (IU/L; median, 46; range, 20-180)	Necroinflammatory score	Modified ISHAK stage fibrosis
PT1	37	M	-	36	180	1/18	0
PT2	53	M	-	2,831	34	1/18	0
PT3	40	M	-	243,818	47	2/18	1
PT4	35	M	-	2,048	46	3/18	1
PT5	42	M	+	447,888	47	4/18	1
PT6	31	F	+	3.24 × 10 ⁸	37	4/18	1
PT7	44	M	-	6,970	45	4/18	1
PT8	32	M	-	2,742	82	4/18	0
PT9	43	F	+	5.19X10 ⁸	20	1/18	1
PT10	40	M	-	448	40	2/18	0
PT11	38	F	+	8.36 × 10 ⁷	71	5/18	3
PT12	33	M	-	68,602	76	4/18	1
PT13	54	M	-	2,300	20	1/18	0
PT14	32	M	-	33,1132	32	2/18	1
PT15	32	M	+	1.07 × 10 ⁷	87	3/18	1
PT16	38	M	-	89	34	1/18	0
PT17	40	M	-	616	27	2/18	2
PT18	28	F	+	3.98 × 10 ⁷	32	5/18	2
PT19	28	M	-	60	90	5/18	3
PT20	48	M	-	7,503	60	2/18	0
PT21	45	M	-	5,652,257	46	5/18	1
HBV patients with liver biopsies only (HLAA2 ⁺ ; n = 5)	Age (median, 34; range, 22-42)	Sex (F/M = 7:2)	HBeAg ⁺ 2/9	HBV DNA (IU/ml; median, 6583, range, 463-9.11 x 10 ⁸)	ALT (IU/liter; median, 28; range, 18-55)	Necroinflammatory score	Modified ISHAK stage fibrosis
PT22	22	F	+	9.11 × 10 ⁸	55	6/18	5
PT23	22	F	-	4,100	30	3/18	1
PT24	40	F	-	9,397	18	3/18	0
PT25	29	F	+	2,040,391	26	3/18	0
PT26	42	F	-	463	28	3/18	3
HBV patients with liver biopsies only HLAA2 ⁻ (n = 4)							
PT27	35	M	-	38,144	28	2/18	1
PT28	31	F	-	631	43	4/18	2
PT 29	40	F	-	6,583	27	NA	3
PT30	34	M	-	796	28	1/18	1

5 HLAA2⁺ HBV patients with available liver biopsies were used for the identification of virus specific CD8 T cells with multimers. No peripheral blood was available.
4 HLAA2⁻ HBV with only available liver biopsies were used for further phenotypic analysis of intrahepatic cells. NA=not available.

Table S2. Patient characteristics with available liver biopsy specimens used as controls

Control biopsies	Age	Sex	HCV RNA	ALT	Necroinflammatory score	Modified ISHAK stage fibrosis
			<i>IU/ml</i>	<i>IU/liter</i>		
HCV	29	F	17,508 Genotype 3a	56	4/18	2
HCV	35	M	599,506 Genotype 1b	380	2/18	1
HCV	29	M	2,300,000	35	4/18	2
HCV	53	F	1,300,000 Genotype 1a	327	4/18	1
HCV	34	M	NA	NA	NA	NA
HCV	36	F	198,441 Genotype 3a	50	3/18	1
HCV	26	M	200,000 Genotype 3a	140	5/18	2
NAFLD	49	M	Not applicable	57	NA	NA
EXPLANTS (<i>n</i> = 7)	NA	NA	Not applicable	NA	NA	NA

NA = not available. No PBMCs were available. Histology report for NAFLD is as follows: Steatohepatitis with moderate steatosis (35%) and significant perivenular fibrosis. Intrahepatic lymphocytes were isolated from *n* = 7 explants from patients with no laboratory evidence of viral hepatitis undergoing resections for liver metastases; specimens were derived from healthy areas surrounding the tumors.

Table S3. HCV patient characteristics with available PBMCs

Patients	Age	Sex	HCV RNA	ALT	Necroinflammatory score	Modified ISHAK stage fibrosis
			<i>IU/ml</i>	<i>IU/liter</i>		
HCV	46	F	1,141,156 Genotype 3a	29	4/18	3
HCV	53	M	172,065 Genotype 1a	180	NA	NA
HCV	51	M	6,477,644 Genotype 1a	42	4/18	3
HCV	33	M	44,966 Genotype 3a	77	2/18	0
HCV	22	M	2,674,206 Genotype 1b	58	3/18	0
HCV	59	M	6,947,070 Genotype 1a	44	4/18	1
HCV	48	M	1,176,210 Genotype 1b	77	6/18	3
HCV	51	M	220,000	29	NA	NA

n = 8 patients. The median age is 49.5 and the age range is 22 to 59 years. The female/male ration is 1:7. For HCV RNA, the median is 1.159e+006 and the range is 44,966–6.947e+006. For ALT, the median is 51 and the range is 29 to 180. NA= not available